Real-World Data Favor ARIs Over Abiraterone in Metastatic Hormone-Sensitive Prostate Cancer
This large Flatiron Health cohort offers the first sizable US community-practice comparison of abiraterone versus enzalutamide or apalutamide intensification in mHSPC, but it cannot replace a randomized trial.
📅 Journal publication: Oct 1, 2026·Last updated: Oct 29, 2026
Androgen receptor inhibitors show longer survival in prostate cancer.
Determining the optimal therapy for metastatic hormone-sensitive prostate cancer (mHSPC) can significantly impact patient survival. Patients treated with androgen receptor inhibitors (ARIs) had a median overall survival of 67.9 months compared to 57.2 months for those on androgen synthesis inhibitors (ASIs). While ARIs showed longer survival in this cohort, the absence of randomized clinical trials limits definitive conclusions. Clinical decisions should consider individual patient factors. Androgen receptor inhibitors may offer longer survival than androgen synthesis inhibitors in mHSPC, pending further trials.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Gebrael G, Jo Y, Nandakumar V, Ozay ZI, Mercinelli C, Hooper G, Ostrowski M, Sayegh N, Lin E, Goel K, Li H, Thomas VM, Gupta S, Guha A, Riaz IB, Agarwal N, Swami U
Citation:Gebrael G, Jo Y, Nandakumar V, et al. Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer. JAMA network open. 2026;9(10):e2639458. doi:10.1001/jamanetworkopen.2026.39458